Sun Pharma gets CDSCO panel nod to additional pack size of Gemcitabine
New Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for the manufacturing and marketing of the chemotherapeutic agent, Gemcitabine Hydrochloride Injection (10mg/ml) for an additional pack size of 2200mg/220ml.
This came in the wake of the proposal presented by the drug giant for an additional pack size for Gemcitabine Hydrochloride Injection (10mg/ml) – 2200mg/220ml.
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers.
Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl in the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that act by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.